<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015195</url>
  </required_header>
  <id_info>
    <org_study_id>JSP-001</org_study_id>
    <nct_id>NCT02015195</nct_id>
  </id_info>
  <brief_title>Effective Treatments for Jellyfish Stings</brief_title>
  <official_title>Efficacy of Topical Agents in the Treatment of Chrysaora Chinensis Stings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to attempt to determine which treatment from commonly used
      treatments is the best at reducing pain and redness of the skin after a sting from a
      Portuguese Man of War, Chrysaora chinensis, or Chrysaora fuscescens.

      Jellyfish stings are a common occurrence in many parts of the world causing significant
      morbidity to persons stung by jellyfish while participating in marine activities whether
      commercial or recreational. Much debate and confusion exist both in the medical literature
      and the common recommendations regarding how to treat persons stung by jellyfish.
      Specifically concerning what topical treatments are most efficacious at decreasing
      envenomation by nematocyst on skin, preventing the firing of un-discharged nematocyst,
      decreasing inflammation and pain resulting from envenomation by nematocyst. Antidotal
      recommendations and past studies have referenced numerous different topical treatments for
      jellyfish stings including but not limited to vinegar, urine, alcohol, distilled spirits,
      ammonia, bleach, acetone, bicarbonate slurry, lidocaine, meat tenderizer, Coca Cola, old
      wine, salt water, cold packs, hot water, and commercial products such as Stingose and
      Stingaid. Conflicting data exists regarding what works and what does not for nematocysts
      discharge, skin erythema, and pain reaction.

      The investigators would like to investigate which treatment is best out of some of the more
      commonly studied treatments for reducing pain and erythema.

      The investigators would like to complete a research study to try to bring some reasonable
      evidence to the field treatment of jellyfish stings, namely, the decontamination process
      (e.g., what can you put on a jellyfish sting that will be helpful, based on real data?).

      The questions asked are as follows:

        -  What topical treatments for jellyfish stings actually decrease the amount of
           inflammation seen on a macroscopic level on the skin of humans?

        -  What topical treatments for jellyfish stings actually decrease the sensation of pain in
           humans?

        -  Do topical chemical treatments cause different outcomes when exposed to the above
           parameters?

        -  Do different species of jellyfish nematocysts react differently based on the type of
           topical chemical treatment used? What is the variation of effects of topical treatments
           based on the species of jellyfish sting?

      Specifically, the investigators will be stinging human subject on both arms with a segment of
      tentacle for approximately 2 minutes. This will be followed by no treatment on one arm
      (control arm) and by treatment on the other arm with either: acetic acid (5%), sodium
      bicarbonate slurry (50%), papain slurry (70%), ammonia (10%), viscous lidocaine (4%),
      isopropyl alcohol (70%), or hot tap water (40 degrees Celsius). Outcomes measured will
      include pain and erythema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Pain in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (17) Taken Over 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Pain is measured on a scale of 1-10 with 0 being no pain and 10 being worse pain ever felt. Baseline pain will be measured immediately after being stung for 2 minutes without any treatment. Subsequent pain felt at every 2 minutes for 30 minutes, at 1 hour post sting, and at 24 hours post sting will be based on changes from the original baseline pain. Mean change is defined as the mean change in pain from all time points measured from each participant and then averaged for each group. The control arm (placebo) was collected and analyzed in parallel to the treatment arm. The &quot;mean change&quot; for the treatment arm was then compared with the &quot;mean change&quot; for the control arm as a baseline. Hence, the data presented are the estimated effect for each treatment group compared to the control arms for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Erythema (Redness) in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (3) Taken Over 24 Hours</measure>
    <time_frame>30 minutes, 1 hour, and 24 hours</time_frame>
    <description>Visual inspection of sting sites will be done at 30 minutes post sting (after treatment completed), 1 hour post sting, and 24 hours post sting. Erythema Index (EI) imeasures increase in cutaneous vasodilation. A computer-measured (Image-J software) EI was used to remove subjectivity. A numeric score was created for the level of erythema, with &quot;0&quot; representing baseline erythema on the control arm. Any positive number indicates more and negative number less erythema on treatment arm compared to placebo. EI values were measured on a &quot;scale&quot; from -20 to +20 with &quot;0&quot; being the midpoint where there would be equal amounts of erythema on both the treatment and control arm. The erythema they experienced on the &quot;treatment arm&quot; was then measured as more erythema (a positive value up to 20) or less erythema (a negative value up to -20).</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Jellyfish Stings</condition>
  <arm_group>
    <arm_group_label>Acetic Acid 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate Slurry (50%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Papain Slurry (70%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Household ammonia (10%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine (4%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isopropyl Alcohol (70%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hot Water (40 degrees Celsius)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acetic Acid (5%)</intervention_name>
    <arm_group_label>Acetic Acid 5%</arm_group_label>
    <other_name>Vinegar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Bicarbonate Slurry (50%)</intervention_name>
    <arm_group_label>Sodium Bicarbonate Slurry (50%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Papain Slurry (70%)</intervention_name>
    <arm_group_label>Papain Slurry (70%)</arm_group_label>
    <other_name>Adolfo's Meat tenderizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ammonia (10%)</intervention_name>
    <arm_group_label>Household ammonia (10%)</arm_group_label>
    <other_name>Household ammonia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine (4%)</intervention_name>
    <arm_group_label>Lidocaine (4%)</arm_group_label>
    <other_name>Liquid Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isopropyl Alcohol (70%)</intervention_name>
    <arm_group_label>Isopropyl Alcohol (70%)</arm_group_label>
    <other_name>Rubbing alcohol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hot Tap Water (40 degrees Celsius)</intervention_name>
    <arm_group_label>Hot Water (40 degrees Celsius)</arm_group_label>
    <other_name>Hot Water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <arm_group_label>Acetic Acid 5%</arm_group_label>
    <arm_group_label>Sodium Bicarbonate Slurry (50%)</arm_group_label>
    <arm_group_label>Papain Slurry (70%)</arm_group_label>
    <arm_group_label>Household ammonia (10%)</arm_group_label>
    <arm_group_label>Lidocaine (4%)</arm_group_label>
    <arm_group_label>Isopropyl Alcohol (70%)</arm_group_label>
    <arm_group_label>Hot Water (40 degrees Celsius)</arm_group_label>
    <other_name>Nothing is given topically to treat sting. This is the control.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-65 years

          -  Healthy volunteers

        Exclusion Criteria:

          -  Known history of allergic reaction or anaphylaxis to prior Cnidaria sting of there
             envenomations

          -  Family history of anaphylaxis to any sting from either Cnidaria, bee, or wasp

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul S Auerbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Emergency Medicine, Stanford University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthieu P DeClerck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Emergency Medicine, Stanford University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <results_first_submitted>January 26, 2015</results_first_submitted>
  <results_first_submitted_qc>April 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2015</results_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Paul S Auerbach</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Jellyfish stings</keyword>
  <keyword>Treatment</keyword>
  <keyword>Humans</keyword>
  <keyword>Topical Treatments</keyword>
  <keyword>Pain</keyword>
  <keyword>Erythema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bites and Stings</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy human subjects were recruited by advertisement on Stanford University campus during the months of May and June, 2013 for a study that took place within a medical ward within a hospital during July, 2013. 97 patients were enrolled.</recruitment_details>
      <pre_assignment_details>Volunteers were excluded if they were pregnant, had a history of allergic reaction to prior jellyfish or insect sting, a family history of severe allergic reaction to jellyfish or insect sting, or a history of heart or lung disease.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acetic Acid 5%</title>
          <description>Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Acetic Acid (5%)
No treatment
The left arm was always the active treatment arm; the right arm was the &quot;control&quot; arm (i.e., no treatment).</description>
        </group>
        <group group_id="P2">
          <title>Sodium Bicarbonate Slurry (50%)</title>
          <description>Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Sodium Bicarbonate Slurry (50%)
No treatment
The left arm was always the active treatment arm; the right arm was the &quot;control&quot; arm (i.e., no treatment).</description>
        </group>
        <group group_id="P3">
          <title>Papain Slurry (70%)</title>
          <description>Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Papain Slurry (70%)
No treatment
The left arm was always the active treatment arm; the right arm was the &quot;control&quot; arm (i.e., no treatment).</description>
        </group>
        <group group_id="P4">
          <title>Household Ammonia (10%)</title>
          <description>Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Ammonia (10%)
No treatment
The left arm was always the active treatment arm; the right arm was the &quot;control&quot; arm (i.e., no treatment).</description>
        </group>
        <group group_id="P5">
          <title>Lidocaine (4%)</title>
          <description>Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Lidocaine (4%)
No treatment
The left arm was always the active treatment arm; the right arm was the &quot;control&quot; arm (i.e., no treatment).</description>
        </group>
        <group group_id="P6">
          <title>Isopropyl Alcohol (70%)</title>
          <description>Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Isopropyl Alcohol (70%)
The left arm was always the active treatment arm; the right arm was the &quot;control&quot; arm (i.e., no treatment).
No treatment</description>
        </group>
        <group group_id="P7">
          <title>Hot Water (40 Degrees Celsius)</title>
          <description>Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Hot Tap Water (40 degrees Celsius)
No treatment
The left arm was always the active treatment arm; the right arm was the &quot;control&quot; arm (i.e., no treatment).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>one patient treated with ammonia - adverse local skin reaction - this treatment arm therefore withdrawn from study</population>
      <group_list>
        <group group_id="B1">
          <title>Acetic Acid 5%</title>
          <description>Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Acetic Acid (5%)
No treatment
11 males, 5 females treated</description>
        </group>
        <group group_id="B2">
          <title>Sodium Bicarbonate Slurry (50%)</title>
          <description>Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Sodium Bicarbonate Slurry (50%)
No treatment
8 males, 8 females treated</description>
        </group>
        <group group_id="B3">
          <title>Papain Slurry (70%)</title>
          <description>Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Papain Slurry (70%)
No treatment
9 males, 7 females treated</description>
        </group>
        <group group_id="B4">
          <title>Household Ammonia (10%)</title>
          <description>Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Ammonia (10%)
No treatment
1 female treated; adverse local skin reaction; study arm therefore withdrawn</description>
        </group>
        <group group_id="B5">
          <title>Lidocaine (4%)</title>
          <description>Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Lidocaine (4%)
No treatment
10 males, 6 females treated</description>
        </group>
        <group group_id="B6">
          <title>Isopropyl Alcohol (70%)</title>
          <description>Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Isopropyl Alcohol (70%)
No treatment
8 makes, 8 females treated</description>
        </group>
        <group group_id="B7">
          <title>Heated Water (40 Degrees Celsius)</title>
          <description>Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Heated Tap Water (40 degrees Celsius)
No treatment
8 males, 8 females treated</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="16"/>
            <count group_id="B7" value="16"/>
            <count group_id="B8" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Pain in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (17) Taken Over 24 Hours</title>
        <description>Pain is measured on a scale of 1-10 with 0 being no pain and 10 being worse pain ever felt. Baseline pain will be measured immediately after being stung for 2 minutes without any treatment. Subsequent pain felt at every 2 minutes for 30 minutes, at 1 hour post sting, and at 24 hours post sting will be based on changes from the original baseline pain. Mean change is defined as the mean change in pain from all time points measured from each participant and then averaged for each group. The control arm (placebo) was collected and analyzed in parallel to the treatment arm. The &quot;mean change&quot; for the treatment arm was then compared with the &quot;mean change&quot; for the control arm as a baseline. Hence, the data presented are the estimated effect for each treatment group compared to the control arms for each group.</description>
        <time_frame>24 hours</time_frame>
        <population>one participant excluded because of adverse local skin reaction to household ammonia</population>
        <group_list>
          <group group_id="O1">
            <title>Acetic Acid 5%</title>
            <description>Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Acetic Acid (5%)
No treatment</description>
          </group>
          <group group_id="O2">
            <title>Sodium Bicarbonate Slurry (50%)</title>
            <description>Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Sodium Bicarbonate Slurry (50%)
No treatment</description>
          </group>
          <group group_id="O3">
            <title>Papain Slurry (70%)</title>
            <description>Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Papain Slurry (70%)
No treatment</description>
          </group>
          <group group_id="O4">
            <title>Lidocaine (4%)</title>
            <description>Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Lidocaine (4%)
No treatment</description>
          </group>
          <group group_id="O5">
            <title>Isopropyl Alcohol (70%)</title>
            <description>Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Isopropyl Alcohol (70%)
No treatment</description>
          </group>
          <group group_id="O6">
            <title>Hot Water (40 Degrees Celsius)</title>
            <description>Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Hot Tap Water (40 degrees Celsius)
No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Pain in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (17) Taken Over 24 Hours</title>
          <description>Pain is measured on a scale of 1-10 with 0 being no pain and 10 being worse pain ever felt. Baseline pain will be measured immediately after being stung for 2 minutes without any treatment. Subsequent pain felt at every 2 minutes for 30 minutes, at 1 hour post sting, and at 24 hours post sting will be based on changes from the original baseline pain. Mean change is defined as the mean change in pain from all time points measured from each participant and then averaged for each group. The control arm (placebo) was collected and analyzed in parallel to the treatment arm. The &quot;mean change&quot; for the treatment arm was then compared with the &quot;mean change&quot; for the control arm as a baseline. Hence, the data presented are the estimated effect for each treatment group compared to the control arms for each group.</description>
          <population>one participant excluded because of adverse local skin reaction to household ammonia</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="-0.31" upper_limit="0.55"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-0.63" upper_limit="0.25"/>
                    <measurement group_id="O3" value="-0.46" lower_limit="-0.90" upper_limit="-0.01"/>
                    <measurement group_id="O4" value="-0.31" lower_limit="-0.76" upper_limit="0.126"/>
                    <measurement group_id="O5" value="-0.26" lower_limit="-0.70" upper_limit="0.17"/>
                    <measurement group_id="O6" value="0.42" lower_limit="-0.02" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Erythema (Redness) in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (3) Taken Over 24 Hours</title>
        <description>Visual inspection of sting sites will be done at 30 minutes post sting (after treatment completed), 1 hour post sting, and 24 hours post sting. Erythema Index (EI) imeasures increase in cutaneous vasodilation. A computer-measured (Image-J software) EI was used to remove subjectivity. A numeric score was created for the level of erythema, with &quot;0&quot; representing baseline erythema on the control arm. Any positive number indicates more and negative number less erythema on treatment arm compared to placebo. EI values were measured on a &quot;scale&quot; from -20 to +20 with &quot;0&quot; being the midpoint where there would be equal amounts of erythema on both the treatment and control arm. The erythema they experienced on the &quot;treatment arm&quot; was then measured as more erythema (a positive value up to 20) or less erythema (a negative value up to -20).</description>
        <time_frame>30 minutes, 1 hour, and 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetic Acid 5%</title>
            <description>Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Acetic Acid (5%)
No treatment</description>
          </group>
          <group group_id="O2">
            <title>Sodium Bicarbonate Slurry (50%)</title>
            <description>Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Sodium Bicarbonate Slurry (50%)
No treatment</description>
          </group>
          <group group_id="O3">
            <title>Papain Slurry (70%)</title>
            <description>Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Papain Slurry (70%)
No treatment</description>
          </group>
          <group group_id="O4">
            <title>Lidocaine (4%)</title>
            <description>Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Lidocaine (4%)
No treatment</description>
          </group>
          <group group_id="O5">
            <title>Isopropyl Alcohol (70%)</title>
            <description>Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Isopropyl Alcohol (70%)
No treatment</description>
          </group>
          <group group_id="O6">
            <title>Hot Water (40 Degrees Celsius)</title>
            <description>Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Hot Tap Water (40 degrees Celsius)
No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Erythema (Redness) in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (3) Taken Over 24 Hours</title>
          <description>Visual inspection of sting sites will be done at 30 minutes post sting (after treatment completed), 1 hour post sting, and 24 hours post sting. Erythema Index (EI) imeasures increase in cutaneous vasodilation. A computer-measured (Image-J software) EI was used to remove subjectivity. A numeric score was created for the level of erythema, with &quot;0&quot; representing baseline erythema on the control arm. Any positive number indicates more and negative number less erythema on treatment arm compared to placebo. EI values were measured on a &quot;scale&quot; from -20 to +20 with &quot;0&quot; being the midpoint where there would be equal amounts of erythema on both the treatment and control arm. The erythema they experienced on the &quot;treatment arm&quot; was then measured as more erythema (a positive value up to 20) or less erythema (a negative value up to -20).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" lower_limit="-3.52" upper_limit="12.39"/>
                    <measurement group_id="O2" value="-12.07" lower_limit="-19.26" upper_limit="-4.88"/>
                    <measurement group_id="O3" value="0.58" lower_limit="-7.37" upper_limit="8.55"/>
                    <measurement group_id="O4" value="-4.14" lower_limit="-11.56" upper_limit="3.27"/>
                    <measurement group_id="O5" value="2.11" lower_limit="-5.84" upper_limit="10.07"/>
                    <measurement group_id="O6" value="-4.11" lower_limit="-11.79" upper_limit="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acetic Acid 5%</title>
          <description>Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Acetic Acid (5%)
No treatment</description>
        </group>
        <group group_id="E2">
          <title>Sodium Bicarbonate Slurry (50%)</title>
          <description>Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Sodium Bicarbonate Slurry (50%)
No treatment</description>
        </group>
        <group group_id="E3">
          <title>Papain Slurry (70%)</title>
          <description>Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Papain Slurry (70%)
No treatment</description>
        </group>
        <group group_id="E4">
          <title>Household Ammonia (10%)</title>
          <description>Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Ammonia (10%)
No treatment
The first patient treated had an adverse local skin reaction, so this study arm was discontinued</description>
        </group>
        <group group_id="E5">
          <title>Lidocaine (4%)</title>
          <description>Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Lidocaine (4%)
No treatment</description>
        </group>
        <group group_id="E6">
          <title>Isopropyl Alcohol (70%)</title>
          <description>Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Isopropyl Alcohol (70%)
No treatment</description>
        </group>
        <group group_id="E7">
          <title>Hot Water (40 Degrees Celsius)</title>
          <description>Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
Hot Tap Water (40 degrees Celsius)
No treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>pain</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>erythema</sub_title>
                <description>erythema</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Auerbach, MD</name_or_title>
      <organization>Division of Emergency Medicine, Department of Surgery, Stanford University School of Medicine</organization>
      <phone>650.725.9445</phone>
      <email>auerbach@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

